4-肼基嘧啶 | 22930-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-肼基嘧啶
• 英文名称: 4-hydrazinylpyrimidine
• 英文别名: pyrimidin-4-ylhydrazine
• CAS: 22930-71-8
• 化学式: C₄H₆N₄
• 分子量: 110.118
• InChiKey: QIEQDFYXVYQLLU-UHFFFAOYSA-N

物化性质

• 熔点：
  132-134 °C (decomp)
• 沸点：
  246.3±23.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-肼基嘧啶 、 2-苯甲酰吡啶 在 硫酸 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 2-benzoylpyridine 4-pyrimidinylhydrazone
  参考文献：
  名称：

  Azinyl and Diazinyl Hydrazones Derived from Aryl N-Heteroaryl Ketones:  Synthesis and Antiproliferative Activity^,

  摘要：

  A series of N-heteroaryl hydrazones derived from aryl N-heteroaryl or bis-N-heteroaryl methanones was prepared in search for potential novel antitumor agents. The stereochemistry of these compounds was established by means of NMR spectroscopy. Antiproliferative activity was determined in a panel of human tumor cell Lines (CCRF-CEM, Burkitt's lymphoma, HeLa, ZR-75-1, HT-29, and MEXF 276L) in vitro. Generally, the new compounds were found to be more patent (IC(50) = 0.011-0.436 mu M) than the ribonucleotide reductase inhibitor hydroxyurea (IC(50) = 140 mu M) Most of the compounds exhibited the highest activity against Burkitt's lymphoma with an IC(50) Of 0.011-0.035 mu M. [(14)C]Cytidine incorporation into DNA was quantitated for selected hydrazones (Z-A, E-1, Z-3, Z-4, E-5, Z-5, E-13, E-18, Z-19, Z-24, and E-26) as a measure of the inhibition of-ribonucleotide reductase in Burkitt's lymphoma cells. The E-configurated compounds were found to inhibit [(14)C]cytidine incorporation to a greater extent (IC(50) = 0.67-5.05 mu M) than the Z-isomers (IC(50) = 7.20 to > 10 mu M). Principal component analysis of the IC(50) values obtained for inhibition of cell proliferation revealed that the cell lines tested can be grouped into three main families showing different sensitivities toward the compounds in our series [(i) CCRF-CEM, Burkitt's lymphoma, and Hela; (ii) HT-29; and (iii) MEXF 276 L].

  DOI：

  10.1021/jm970255w
• 作为产物：
  描述：

  4-氯-6-肼基嘧啶 在 palladium on activated charcoal ammonium formate 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成 4-肼基嘧啶
  参考文献：
  名称：

  Azinyl and Diazinyl Hydrazones Derived from Aryl N-Heteroaryl Ketones:  Synthesis and Antiproliferative Activity^,

  摘要：

  A series of N-heteroaryl hydrazones derived from aryl N-heteroaryl or bis-N-heteroaryl methanones was prepared in search for potential novel antitumor agents. The stereochemistry of these compounds was established by means of NMR spectroscopy. Antiproliferative activity was determined in a panel of human tumor cell Lines (CCRF-CEM, Burkitt's lymphoma, HeLa, ZR-75-1, HT-29, and MEXF 276L) in vitro. Generally, the new compounds were found to be more patent (IC(50) = 0.011-0.436 mu M) than the ribonucleotide reductase inhibitor hydroxyurea (IC(50) = 140 mu M) Most of the compounds exhibited the highest activity against Burkitt's lymphoma with an IC(50) Of 0.011-0.035 mu M. [(14)C]Cytidine incorporation into DNA was quantitated for selected hydrazones (Z-A, E-1, Z-3, Z-4, E-5, Z-5, E-13, E-18, Z-19, Z-24, and E-26) as a measure of the inhibition of-ribonucleotide reductase in Burkitt's lymphoma cells. The E-configurated compounds were found to inhibit [(14)C]cytidine incorporation to a greater extent (IC(50) = 0.67-5.05 mu M) than the Z-isomers (IC(50) = 7.20 to > 10 mu M). Principal component analysis of the IC(50) values obtained for inhibition of cell proliferation revealed that the cell lines tested can be grouped into three main families showing different sensitivities toward the compounds in our series [(i) CCRF-CEM, Burkitt's lymphoma, and Hela; (ii) HT-29; and (iii) MEXF 276 L].

  DOI：

  10.1021/jm970255w

文献信息

• [EN] GPR139 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR139
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2020097609A1

  公开（公告）日：2020-05-14

  Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

  提供了调节GPR139受体的化合物，含有这些化合物的组合物，以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的失调的方法。这些化合物具有Formula（X）的结构或其在药学上可接受的异构体，消旋体，水合物，溶剂合物，同位素或盐，其中R1，R2，R3，R4，R9，R10，R11和R12，Q5，Q6，Q7和Q8如本文所定义。
• [EN] HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE TRANSPORT NUCLÉAIRE CONTENANT DE L'HYDRAZIDE ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2013019548A1

  公开（公告）日：2013-02-07

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  这项发明通常与核运输调节剂有关，例如CRM1抑制剂，更具体地涉及一种由结构式(I)表示的化合物，或其药学上可接受的盐，其中变量的值和备选值如本文所定义和描述。该发明还包括合成和使用结构式I的化合物，或其药学上可接受的盐或组合物，例如在与CRM1活性相关的生理状况的治疗、调节和/或预防中的应用。
• Synthesis of Halogen-Substituted Pyridyl and Pyrimidyl Derivatives of [3,2-<i>c</i>]Pyrazolo Corticosteroids:  Strategies for the Development of Glucocorticoid Receptor Mediated Imaging Agents
  作者：Robert M. Hoyte、Jing-xin Zhang、Ronald Lerum、Aladejebi Oluyemi、Prita Persaud、Craig O'Connor、David C. Labaree、Richard B. Hochberg

  DOI：10.1021/jm0202775

  日期：2002.11.1

  Ligands for the glucocorticoid receptor labeled with high-energy isotopes are highly desired for their potential applications in nuclear medical studies of the brain where the dysregulation of this receptor system is thought to be involved in various neurodegenerative disorders. Analogues of the glucocorticoid cortivazol have previously been prepared as target compounds for labeling with high-energy

  迫切需要具有高能同位素标记的糖皮质激素受体的配体，因为它们在脑的核医学研究中具有潜在的应用前景，认为该受体系统的失调与多种神经退行性疾病有关。先前已经制备了糖皮质激素考替唑的类似物作为用于用高能同位素标记的目标化合物。然而，这种类型的芳基吡唑的苯环没有充分活化以进行放射性卤代类似物的合成通常所需的亲核取代反应。由于适当取代的芳族氮杂环基适合亲核取代，这项研究的目标是合成类似于Cortivazol的吡啶基吡唑和嘧啶基吡唑类似物，可以在吡啶或嘧啶环中用放射性卤素标记。我们描述了几个在吡唑环的2'位置含有吡啶基，卤代吡啶基和嘧啶基取代基的[3,2-c]吡唑并类固醇的合成。测试了这些化合物与糖皮质激素受体的结合以及在组织培养中生长的对糖皮质激素有反应的HeLa细胞中的生物学活性。在吡啶基和嘧啶基衍生物中，2'-（3-吡啶基）-11 beta，17,21-三羟基-16α-甲基-20-氧杂泼尼-4-eno
• [EN] N-PYRIMIDINYL HYDROXY PYRAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'HYDROXY PYRAZOLE N-PYRIMIDINYLE ET UTILISATIONS ASSOCIÉES
  申请人：CADO BIOTECHNOLOGY IVS

  公开号：WO2019141957A1

  公开（公告）日：2019-07-25

  There is provided herein a compound of formula (I) or a pharmaceutically acceptable salt and/or prodrug thereof, for use in the treatment or prevention of a fungal or bacterial infection wherein R1 to R5 have meanings provided in the description. There is also provided certain compounds and methods for preparating the same.

  本文提供了一种式子（I）的化合物或其药学上可接受的盐和/或前药，用于治疗或预防真菌或细菌感染，其中R1至R5的含义在说明中提供。还提供了某些化合物和制备它们的方法。
• p38 MAP kinase inhibitors
  申请人：——

  公开号：US20010044538A1

  公开（公告）日：2001-11-22

  The present invention relates to compounds of Formula (I) 1 that are p-38 MAP kinase inhibitors, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

  本发明涉及公式（I）1的化合物，它们是p-38 MAP激酶抑制剂，包含它们的制药组合物，使用它们的方法，以及制备这些化合物的方法。